# MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

> **NCT06586515** · PHASE1 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 630 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Non-small Cell Lung Cancer
- Colorectal Cancer

## Interventions

- **DRUG:** LY3962673
- **DRUG:** Cetuximab
- **DRUG:** Gemcitabine
- **DRUG:** nab-paclitaxel
- **DRUG:** Oxaliplatin
- **DRUG:** leucovorin
- **DRUG:** Irinotecan
- **DRUG:** 5-fluorouracil

## Key facts

- **NCT ID:** NCT06586515
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-12
- **Primary completion:** 2029-03
- **Final completion:** 2029-03
- **Target enrollment:** 630 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06586515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06586515, "MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06586515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*